Therapeutic approaches to target alpha-synuclein pathology

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Alpha-synuclein is genetically linked to Parkinson's disease (PD) risk.
• Aggregated alpha-synuclein forms Lewy pathology, a hallmark of PD and related synucleinopathies.
• Pathological alpha-synuclein can spread through the nervous system, worsening symptoms.

Purpose of the Study:

• To review current challenges and possibilities for alpha-synuclein as a therapeutic target.
• To highlight knowledge gaps in alpha-synuclein pathobiology.
• To discuss various therapeutic strategies and clinical trial challenges.

Main Methods:

• Literature review of alpha-synuclein research and therapeutic approaches.
• Categorization of treatments based on their mechanism of action.
• Discussion of challenges in clinical development.

Main Results:

• Alpha-synuclein remains a primary target for PD and synucleinopathies.
• Multiple therapeutic strategies are under investigation, including reducing production, inhibiting aggregation, promoting degradation, and limiting cell-to-cell spread.
• Clinical trials face challenges in monitoring target engagement and require significant duration and patient numbers.

Conclusions:

• Understanding alpha-synuclein pathobiology is crucial for developing improved therapies.
• Numerous therapeutic approaches offer promise for treating synucleinopathies.
• Continued research and clinical trials are essential for advancing treatment options.